Lamotrigine-induced rash - Worth a rechallenge

Acta Neurologica Scandinavica

Volumn 111, Issue 3, 2005, Pages 191-194

  Codrea, Simona P ^a,b   Sidenius, P ^a   Dam, M ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE   (United States)

Author keywords

Lamotrigine; Rash; Rechallenge

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; GABAPENTIN; LAMOTRIGINE; NITRAZEPAM; OXCARBAZEPINE; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOCAL EPILEPSY; GENDER; GENERALIZED EPILEPSY; HUMAN; HYPERSENSITIVITY REACTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRACTICE GUIDELINE; PROVOCATION TEST; RASH; RISK FACTOR; SCHOOL CHILD;

ANTICONVULSANTS; EPILEPSY, GENERALIZED; EXANTHEMA; HUMANS; RETROSPECTIVE STUDIES; RISK FACTORS; TRIAZINES; VALPROIC ACID;

EID: 14044253468     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2005.00381.x     Document Type: Article

References (34)

1. FITTON A, GOA LK. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995;50:691-713.
2. BRODIE MJ, RICHENS A, YUEN AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.
3. BRODIE MJ, OVERSTALL PW, GIORGI L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999;37:81-7.
4. STEINER TJ, DELLAPORTAS CI, FINDLEY LJ et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999;40:601-7.
5. GUBERMAN AH, BESAG FM, BRODIE MJ et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999;40:985-91.
6. WONG IC, MAWER GE, SANDER JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999;33:1037-42.
7. CALABRESE JR, SULLIVAN JR, BOWDEN CL et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002;63:1012-19.
8. FAUGHT E, MORRIS G, JACOBSON M et al. Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group. Epilepsia 1999;40:1135-40.
9. RICHENS A. Safety of lamotrigine. Epilepsia 1994;35(Suppl. 5):S37-40.
10. BESAG FMC, WALLACE SJ, DULAC O et al. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127:991-7.
11. PELLOCK JM. Overview of lamotrigine and the new anti-epileptic drugs: the challenge. J Child Neurol 1997;12(Suppl. 1):S48-52.
12. BERAN RG, BERKOVIC SF, DUNAGAN FM et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalized epilepsy. Epilepsia 1998;39:1329-33.
13. MATUSOF. Lamotrigine. Epilepsia 1999;40(Suppl. 5):S30-6.
14. CULY CR, GOA KL. Lamotrigine. A review of its use in childhood epilepsy. Pediatr Drugs 2000;2:299-330.
15. HIRSCH LJ, WEINTRAUB D, CLAASSEN JA et al. Predicting rash from lamotrigine: results from review of 951 patients. Abstract. Epilepsia 2003;44(Suppl. 9):S277.
16. BURGOS J, MORRIS GL, SMITH P. Rash frequency with lamotrigine use. Abstr Epilepsia 2003;44(Suppl. 9):S275.
17. MESSENHEIMER J. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 1998;25:S14-8.
18. HIRSCH LJ, WEINTRAUB D, Du Y et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004;63:1022-6.
19. GILLHAM R, KANE K, BRYANT-COMSTOCK L, BRODIE MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000;9:375-9.
20. KALVAINEN R, TIGARAN S, KERSNEN T, PELTOLA J, EIKIS M. Open, multicenter randomised comparison of cognitive effects of lamotrigine and slow released carbamazepine monotherapy in newly diagnosed patients with epilepsy. Epilepsia 2002;43(Suppl. 8):47.
21. ALDENKAMP AP, KROM MD, REIJS R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003;44(Suppl. 4):21-9.
22. ETTINGER A, REED M, CRAMER J, EPILEPSY IMPACT PROJECT GROUP. Depression and comorbidity in community-based patients with epilepsy or asthma. Neurology 2004;63: 1008-14.
23. BOWDEN CL, ASNIS GM, GINSBERG LD et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004;27:173-84.
24. KETTER TA, WANG PW, NOWAKOWSKA C, MARSH WK. New medication treatment options for bipolar disorders. Acta Psychiatr Scand Suppl 2004;422:18-33.
25. MORRELL MJ. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 2003;44(Suppl. 4):11-20.
26. SABERS A, DAM M, A-ROGVI-HANSEN B et al. Epilepsy and pregnancy, lamotrigine as main drug used. Acta Neurol Scand 2004;109:9-13.
27. RZANY B, CORREIA O, KELLY JP et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999;353:2190-4.
28. BACHOT N, ROUJEAU JC. Physiopathology and treatment of severe drug eruptions. Current opinion in allergy and clinical immunology 2001;1:293-8.
29. MESSENHEIMER J, MULLENS EL, GIORGI L et al. Safety review of adult clinical experience with lamotrigine. Drug Saf 1998;18:281-96.
30. TAVERNOR SJ, WONG ICK, NEWTON R et al. Rechallenge with lamotrigine after initial rash. Seizure 1995;4:67-71.
31. BESAG FMC, NG GYT, POOL F. Successful re-introduction of lamotrigine after initial rash. Seizure 2000;9:282-6.
32. SCHWAN LM, ETTINGER A, DEVINSKY O. Incidence of rash after rapid reintroduction of lamotrigine. Neurology 2003;60 (Suppl. 1):A146.
33. BUZAN RD, DUBOVSKY SL. Recurrence of lamotrigine-associated rash with re-challenge. J Clin Psychiatry 1998;59:87.
34. MANFREDI G, PACCHIAROTTI I, KOTZALIDIS GD, RUBERTO A, GIARDI P, TATARELLI R. Successful rechallenge with slowly titrated lamotrigine after rash. Letter to the Editor. Bipolar Disord 2004;6:338-9.